We are live on
!
Find out more
NCM
NEXTBio Capital Management Portfolio holdings
AUM
$217M
This Fund
S&P 500
This Quarter
Est. Return
+76.52%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$170M
AUM Growth
–
Cap. Flow
+$158M
Cap. Flow
% of AUM
92.96%
Top 10 Holdings %
Top 10 Hldgs %
70.02%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
quarters
Top 10 Avg Time Held
0
quarters
Top 20 Avg Time Held
0
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protagonist Therapeutics
PTGX
|
+$18.8M |
| 2 |
Vor Biopharma
VOR
|
+$18.6M |
| 3 |
Terns Pharmaceuticals
TERN
|
+$12.7M |
| 4 |
Verastem
VSTM
|
+$11.7M |
| 5 |
Zenas BioPharma
ZBIO
|
+$10.6M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Terns Pharmaceuticals
TERN
| $22.3M | 13.06% |
+551,190
| New | +$12.7M |
2025 Q4
0 quarters
|
|
|
2
Protagonist Therapeutics
PTGX
$8.96B
| $20.1M | 11.76% |
+229,619
| New | +$18.8M |
2025 Q4
0 quarters
|
|
|
3
Vor Biopharma
VOR
$1.13B
| $13.1M | 7.67% |
+999,967
| New | +$18.6M |
2025 Q4
0 quarters
|
|
|
4
Zenas BioPharma
ZBIO
$1.64B
| $11.7M | 6.86% |
+321,983
| New | +$10.6M |
2025 Q4
0 quarters
|
|
5
Shattuck Labs
STTK
$551M
| $11.5M | 6.74% |
+3,149,907
| New | +$7.52M |
2025 Q4
0 quarters
|
|
|
6
Verastem
VSTM
$675M
| $10.1M | 5.92% |
+1,307,330
| New | +$11.7M |
2025 Q4
0 quarters
|
|
7
Palvella Therapeutics
PVLA
$1.85B
| $8.65M | 5.08% |
+82,686
| New | +$7.05M |
2025 Q4
0 quarters
|
|
8
Xenon Pharmaceuticals
XENE
$3.33B
| $8.23M | 4.83% |
+183,704
| New | +$7.72M |
2025 Q4
0 quarters
|
|
9
Rhythm Pharmaceuticals
RYTM
$5.96B
| $7.23M | 4.24% |
+67,586
| New | +$7.17M |
2025 Q4
0 quarters
|
|
10
Structure Therapeutics
GPCR
$1.59B
| $6.57M | 3.85% |
+94,443
| New | +$3.86M |
2025 Q4
0 quarters
|
|
11
Inventiva
IVA
$678M
| $6.04M | 3.54% |
+1,298,701
| New | +$6.03M |
2025 Q4
0 quarters
|
|
12
Compass Therapeutics
CMPX
$154M
| $5.98M | 3.51% |
+1,114,005
| New | +$5.14M |
2025 Q4
0 quarters
|
|
13
Compass Pathways
CMPS
$1.54B
| $5.19M | 3.05% |
+752,631
| New | +$4.59M |
2025 Q4
0 quarters
|
|
14
Oric Pharmaceuticals
ORIC
$1.17B
| $5.04M | 2.95% |
+615,720
| New | +$7.09M |
2025 Q4
0 quarters
|
|
15
Crescent Biopharma
CBIO
$480M
| $4.42M | 2.59% |
+372,856
| New | +$4.75M |
2025 Q4
0 quarters
|
|
16
Vaxcyte
PCVX
$10.4B
| $4.41M | 2.58% |
+95,485
| New | +$4.27M |
2025 Q4
0 quarters
|
|
17
Evommune Inc
EVMN
$213M
| $3.91M | 2.29% |
+228,286
| New | +$4.29M |
2025 Q4
0 quarters
|
|
18
Cogent Biosciences
COGT
$4.87B
| $3.4M | 2% |
+95,819
| New | +$2.69M |
2025 Q4
0 quarters
|
|
19
Disc Medicine
IRON
$2.17B
| $3.4M | 1.99% |
+42,778
| New | +$3.61M |
2025 Q4
0 quarters
|
|
20
Oculis Holding
OCS
$469M
| $2.99M | 1.75% |
+149,750
| New | +$3M |
2025 Q4
0 quarters
|
|
21
Zai Lab
ZLAB
$2.59B
| $2.88M | 1.69% |
+163,362
| New | +$3.82M |
2025 Q4
0 quarters
|
|
22
DELISTED
KalVista Pharmaceuticals
KALV
| $2.13M | 1.25% |
+131,796
| New | +$1.75M |
2025 Q4
0 quarters
|
|
23
Adicet Bio
ACET
$47.8M
| $1.33M | 0.78% |
+157,827
| New | +$1.74M |
2025 Q4
0 quarters
|
|
Similar funds
HIMS
CWM
WWM
CA
ECM
RFM
DCM
TCM
NEXTBio Capital Management's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for NEXTBio Capital Management, which disclosed 23 positions worth $170M. Its ten largest holdings account for 70% of the portfolio.
Its largest position is Protagonist Therapeutics: 229,619 shares worth $20.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- NEXTBio Capital Management's largest Q4 2025 buy was Protagonist Therapeutics: 229,619 shares worth $20.1M.
- NEXTBio Capital Management's ten largest holdings make up 70% of its $170M portfolio in Q4 2025.
- NEXTBio Capital Management disclosed 23 positions in Q4 2025, its first 13F filing on record.
Based on NEXTBio Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.